Literature DB >> 9521271

Paraneoplastic necrotizing myopathy: clinical and pathological features.

M I Levin1, T Mozaffar, M T Al-Lozi, A Pestronk.   

Abstract

OBJECTIVE: To characterize the clinical features and muscle pathology of paraneoplastic necrotizing myopathy.
BACKGROUND: Paraneoplastic syndromes involving many levels of the nervous system are well described, but there are only rare case reports of a necrotizing myopathy associated with cancer.
DESIGN: Case series.
RESULTS: We identified four patients with paraneoplastic necrotizing myopathy from muscle biopsies done at Washington University over a 10-year period. The patients (aged 38 to 76 years) presented with subacutely evolving, symmetric, proximal weakness. Tumor types included gastrointestinal adenocarcinoma (2 of 4), transitional cell carcinoma, prostatic carcinoma, and non-small cell lung carcinoma. Two patients died. Two others improved after treatment that included corticosteroids and tumor resection. Muscle pathology showed numerous necrotic fibers (8 to 100%) and intense alkaline phosphatase staining of the muscle connective tissue, but little inflammation.
CONCLUSIONS: Paraneoplastic necrotizing myopathy is characterized by a rapidly progressive, symmetric, predominantly proximal weakness that produces severe disability. Muscle pathology demonstrates prominent necrosis with alkaline phosphatase staining of connective tissue and little inflammation. Evaluation for cancer is indicated in patients with these clinical and pathologic findings.

Entities:  

Mesh:

Year:  1998        PMID: 9521271     DOI: 10.1212/wnl.50.3.764

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

1.  Unusual manifestations in two cases of necrotizing myopathy associated with SRP antibodies.

Authors:  F Hanisch; T Müller; G Stoltenburg; S Zierz
Journal:  Rheumatol Int       Date:  2011-12-27       Impact factor: 2.631

2.  Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review.

Authors:  Elena Pentsova; Anli Liu; Marc Rosenblum; Eileen O'Reilly; Xi Chen; Adília Hormigo
Journal:  J Neurooncol       Date:  2011-08-03       Impact factor: 4.130

Review 3.  The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Authors:  Ilaria Cavazzana; Micaela Fredi; Carlo Selmi; Angela Tincani; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 4.  Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.

Authors:  Pari Basharat; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.592

5.  Mystery case: a 63-year-old man with progressive proximal pain and weakness.

Authors:  Patricia D Scripko; Anthony A Amato; Alberto Puig
Journal:  Neurology       Date:  2014-01-28       Impact factor: 9.910

6.  Myopathy with antibodies to the signal recognition particle: clinical and pathological features.

Authors:  T Miller; M T Al-Lozi; G Lopate; A Pestronk
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

7.  Clinico-serologic features of statin-induced necrotising autoimmune myopathy in a single-centre cohort.

Authors:  Michael J Waters; Vidya Limaye
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

Review 8.  Neurologic paraneoplastic syndromes.

Authors:  Edward J Dropcho
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

9.  Paraneoplastic necrotizing myopathy in a woman with breast cancer: a case report.

Authors:  Joana Silvestre; Luis Santos; Vitor Batalha; Ana Del Rio; Carlos Lima; Antonio Carvalho; Ana Martins; Helena Miranda; Fatima Cabral; Adelia Felix; Ana Aleixo
Journal:  J Med Case Rep       Date:  2009-11-02

10.  Paraneoplastic Necrotizing Myopathy with a Mild Inflammatory Component: A Case Report and Review of the Literature.

Authors:  Susanne Wegener; Juliane Bremer; Paul Komminoth; Hans H Jung; Michael Weller
Journal:  Case Rep Oncol       Date:  2010-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.